ArticleFrontiers in oncology2025
Primary gastric SMARCA4-deficient carcinosarcoma and sarcomatoid carcinoma: Two case reports.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A mouse model of HPV-associated cervicovaginal carcinosarcoma with comparative analysis to human clinical cases.Cell & bioscience · 2026Article
- Concomitant occurrence of primary gastric sarcomatoid carcinoma and giant gastrointestinal stromal tumor: a case report and literature review.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric SMARCA4-deficient carcinosarcoma and sarcomatoid carcinoma are rare with poor prognosis. In the present study, two male patients were hospitalized due to abdominal manifestations, specifically abdominal pain and a sense of fullness and discomfort. Gastroscopic examination revealed huge raised lesions in the stomach of both individuals, subsequently leading to laparoscopic radical total gastrectomy. Histopathological analysis of surgical specimens obtained from both patients demonstrated the presence of carcinomatous and sarcomatous components. In Case 1, the sarcoma region was negative for the SMARCA4, epithelial markers cytokeratin (CK) and epithelial membrane antigen (EMA), CK, EMA, and SMARCA4 were positively expressed in the adenocarcinoma area, thereby warranting carcinosarcoma diagnosis. The sarcomatous component was identified as a tumor characterized by SMARCA4 deficiency. In Case 2, the tumor cells exhibited positive staining for CK and Vimentin, negative staining for SMARCA4, and the patient was positive for SMARCA4-deficient sarcomatoid carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.